Quick Answer
ZEVRA THERAPEUTICS, INC. reported R&D Expense of $10.16 million for fiscal year 2021.
ZEVRA THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2021 | $10.16M | +14.9% |
| 2020 | $8.84M | -54.5% |
| 2019 | $19.41M | -53.5% |
| 2018 | $41.76M | +102.8% |
| 2017 | $20.59M | +0.6% |
| 2016 | $20.47M | +47.0% |
| 2015 | $13.93M | +16.9% |
| 2014 | $11.92M | +253.9% |
| 2013 | $3.37M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $3.08M | +36.1% | +37.7% |
| September 30, 2021 | $2.24M | +31.0% | -21.4% |
| June 30, 2021 | $2.85M | +45.8% | +25.7% |
| March 31, 2021 | $2.27M | +6.5% | +32.5% |
| September 30, 2020 | $1.71M | -52.7% | -12.5% |
| June 30, 2020 | $1.95M | -59.3% | -8.1% |
| March 31, 2020 | $2.13M | -75.1% | -41.2% |
| September 30, 2019 | $3.62M | -72.9% | -24.7% |
- ZEVRA THERAPEUTICS, INC. showed an increase of +14.9% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2021 period, ZEVRA THERAPEUTICS, INC.’s r&d expense has grown by 201.8% (from $3.37 million to $10.16 million).
- The most recent figure is from ZEVRA THERAPEUTICS, INC.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 31, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: